Akebia Therapeutics annual debt-to-equity ratio
2018
2019
2020
2021
2022
2025
Akebia Therapeutics Debt-to-Equity Ratio Growth & History (AKBA)
Akebia Therapeutics's debt-to-equity ratio was 1.59 for fiscal 2025.
View full Akebia Therapeutics company overviewAkebia Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.59 | — | — |
| 2022 | 2022-12-31 | 19.08 | 17.24 | +935.30% |
| 2021 | 2021-12-31 | 1.84 | 1.33 | +256.53% |
| 2020 | 2020-12-31 | 0.52 | 0.24 | +87.47% |
| 2019 | 2019-12-31 | 0.28 | 0.25 | +1068.88% |
| 2018 | 2018-12-31 | 0.02 | — | — |
Akebia Therapeutics quarterly debt-to-equity ratio
Q1.14
Q2.14
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.19 | 0.37 | +20.18% |
| Q1 2026 | 2026-03-31 | 1.86 | −0.34 | −15.40% |
| Q4 2025 | 2025-12-31 | 1.59 | — | — |
| Q3 2025 | 2025-09-30 | 1.26 | — | — |
| Q2 2025 | 2025-06-30 | 1.83 | — | — |
| Q1 2025 | 2025-03-31 | 2.20 | — | — |
| Q4 2022 | 2022-12-31 | 19.08 | 17.24 | +935.30% |
| Q3 2022 | 2022-09-30 | 12.26 | 11.36 | +1260.63% |
| Q2 2022 | 2022-06-30 | 2.28 | 1.57 | +220.30% |
| Q1 2022 | 2022-03-31 | 6.00 | 5.42 | +924.97% |
| Q4 2021 | 2021-12-31 | 1.84 | 1.33 | +256.53% |
| Q3 2021 | 2021-09-30 | 0.90 | 0.57 | +171.73% |
| Q2 2021 | 2021-06-30 | 0.71 | 0.43 | +148.21% |
| Q1 2021 | 2021-03-31 | 0.59 | 0.31 | +116.16% |
| Q4 2020 | 2020-12-31 | 0.52 | 0.24 | +87.47% |
| Q3 2020 | 2020-09-30 | 0.33 | 0.26 | +360.05% |
| Q2 2020 | 2020-06-30 | 0.29 | 0.22 | +328.29% |
| Q1 2020 | 2020-03-31 | 0.27 | 0.21 | +326.43% |
| Q4 2019 | 2019-12-31 | 0.28 | 0.25 | +1068.88% |
| Q3 2019 | 2019-09-30 | 0.07 | — | — |
| Q2 2019 | 2019-06-30 | 0.07 | — | — |
| Q1 2019 | 2019-03-31 | 0.06 | — | — |
| Q4 2018 | 2018-12-31 | 0.02 | — | — |
| Q2 2014 | 2014-06-30 | 0.00 | — | — |
| Q1 2014 | 2014-03-31 | 0.00 | — | — |
Akebia Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Akebia Therapeutics's debt-to-equity ratio increased from 0.52 to 1.59, a change of 1.07. The latest reported quarter, Q2 2026, shows 2.19.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Akebia Therapeutics source filings ↗